Toll-like receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Steven Ruggles (born May 8, 1955) is Regents Professor of History and Population Studies at the University of Minnesota, and the director of the IPUMS Center for Data Integration. He received a 2022 MacArthur "Genius" award. Ruggles is best known as the creator of IPUMS, the world's largest population database. IPUMS provides information about two billion people residing in 159 countries between 1703 and the present, including every respondent to the surviving U.S. censuses of 1790 to 1950. He served as founding director of the Minnesota Population Center from 2000 to 2016 and the Institute for Social Research and Data Innovation from 2016 to 2023. He served as the 2015 President of the Population Association of America, the first historian to hold the position. He also served as President of the Association of Population Centers (2017–2018) and President of the Social Science History Association (2018–2019). He has been active on many national advisory and study committees, including the Census Bureau Scientific Advisory Committee; the National Science Foundation Social, Behavioral, and Economic Sciences Advisory Committee; the National Science Foundation Advisory Committee for CyberInfrastructure; and the National Academy of Sciences Board on Research Data and Information. Ruggles completed a BA at the University of Wisconsin–Madison (1978), followed by at the University of Pennsylvania an MA (1982) and PhD (historical demography, 1984).
In biochemistry, a transferase is any one of a class of enzymes that catalyse the transfer of specific functional groups (e.g. a methyl or glycosyl group) from one molecule (called the donor) to another (called the acceptor). They are involved in hundreds of different biochemical pathways throughout biology, and are integral to some of life's most important processes. Transferases are involved in myriad reactions in the cell. Three examples of these reactions are the activity of coenzyme A (CoA) transferase, which transfers thiol esters, the action of N-acetyltransferase, which is part of the pathway that metabolizes tryptophan, and the regulation of pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl CoA. Transferases are also utilized during translation. In this case, an amino acid chain is the functional group transferred by a peptidyl transferase. The transfer involves the removal of the growing amino acid chain from the tRNA molecule in the A-site of the ribosome and its subsequent addition to the amino acid attached to the tRNA in the P-site. Mechanistically, an enzyme that catalyzed the following reaction would be a transferase:
Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete. In 2009, an article in Europace journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter defibrillators (ICD).
=== Bombing test === This method applies to objects that are supposedly hermetically sealed such as implantable medical devices, crystal oscillator, saw filter devices, transistors, microprocessors, etc. First the device under test will be exposed to helium pressure (typically 30-60psi) in a "bombing" chamber for an extended time period. If the part is leaky, helium will be able to penetrate the device. Later the device will be placed in a vacuum chamber, connected to a vacuum pump and a mass spectrometer. The tiny amount of gas that entered the device under pressure will be released in the vacuum chamber and sent to the mass spectrometer where the leak rate will be measured down to 10−9 mbar·L·s−1. This method is not able to detect a massive leak as the tracer gas will be quickly pumped out when test chamber is pumped down.
Comfort temperature is interchangeable with neutral temperature in the scientific literature, which can be calculated through regression analysis between thermal sensation votes and indoor temperature. The neutral temperature is the solution of the resulting regression model by setting the thermal sensation vote as zero. The American Heritage Dictionary of the English Language identifies room temperature as around 20–22 °C (68–72 °F; 293–295 K), while the Oxford English Dictionary states that it is "conventionally taken as about 20 °C (68 °F; 293 K)". Ideal room temperature varies vastly depending on the surrounding climate . Studies from Indonesia have shown that the range of comfortable temperature is 24–29 °C (75–84 °F) for local residents. Studies from Nigeria show a comfortable temperature range of 26–28 °C (79–82 °F), comfortably cool 24–26 °C (75–79 °F) and comfortably warm 28–30 °C (82–86 °F). A field study conducted in Hyderabad, India returned a comfort band of 26–32.45 °C (79–90 °F) with a mean of 29.23 °C (85 °F). A study conducted in Jaipur, India among healthy young men showed that the neutral thermal comfort temperature was analyzed to be 30.15 °C (86 °F), although a range of 25.9–33.8 °C (79–93 °F) was found. People are highly sensitive to even small differences in environmental temperature. At 24 °C (75 °F), a difference of 0.38 °C (0.68 °F) can be detected between the temperature of two rooms.
Sources: en.wikipedia.org
Agricultural technology Food biotechnology Food packaging Food grading Molecular gastronomy Optical sorting Standard components (food processing) List of food and drink awards § Food technology awards Timeline of culinary technologies
== Non-traditional use == In the late 20th century, the practice of ayahuasca drinking began spreading to Europe, North America and elsewhere. The first ayahuasca churches, affiliated with the Brazilian Santo Daime, were established in the Netherlands. A legal case was filed against two of the Church's leaders, Hans Bogers (one of the original founders of the Dutch Santo Daime community) and Geraldine Fijneman (the head of the Amsterdam Santo Daime community). Bogers and Fijneman were charged with distributing a controlled substance (DMT); however, the prosecution was unable to prove that the use of ayahuasca by members of the Santo Daime constituted a sufficient threat to public health and order such that it warranted denying their rights to religious freedom under ECHR Article 9. The 2001 verdict of the Amsterdam district court is an important precedent. Since then groups that are not affiliated to the Santo Daime have used ayahuasca, and a number of different "styles" have been developed, including non-religious approaches. In Peru, retreat centers such as Blue Morpho, founded by Hamilton Souther, in Iquitos began offering ayahuasca ceremonies to foreign visitors around 2004. International media coverage brought wider attention to the practice and coincided with the growth of ayahuasca tourism.
== Commercial production == Large-scale commercial cherry juice production is typically produced using a hot extraction or a cold extraction method. Hot extraction involves heating the cherries, pressing them, and then straining and filtering to remove solids. Hot pressed cherry juice typically has a deeper coloration compared to that produced using cold extraction. The heating of the fruit also serves to prevent the juice from browning, because the heating stops natural enzymic actions that occur when the fruit is macerated. Cold extraction involves first removing the pits from fresh cherries and then pressing them and collecting the juice. The juice is then heated to kill microorganisms, stop enzyme activity and to solidify particulate matter prior to filtering. As with hot-extracted juice, the cold-extracted juice is also typically strained and filtered. Cold-extracted cherry juice has a greater likeness to the flavor of fresh cherries, and its coloration is lighter compared to that of hot-extracted juice. Frozen cherries are sometimes used, which enables the creation of a juice that has the cherry-like flavor of cold-extracted juice and a deeper coloration such as that produced by hot extraction. Ascorbic acid is sometimes added as a color stabilizer prior to the cherries being pressed. The juice is typically filtered and clarified prior to being packaged, and pasteurization or flash pasteurization is typically utilized. It is sometimes processed as a frozen concentrate.
planifolia seeds this way are Eulaema polychroma and Scaptotrigona subobscuripennis. Seeds being distributed by bees is a rare behavior and has only been documented in three species of tropical trees previously, the cadaghi (Corymbia torelliana), Coussapoa asperifolia subsp. magnifolia, and Zygia racemosa. Both rodents and marsupials are confirmed to consume fallen pods on the forest floor. Specific species observed eating the pods include Tome's spiny rat (Proechimys semispinosus) and the common opossum (Didelphis marsupialis). Further experiments by a team led by Dr. Adam Karremans showed that the seeds remained viable after being passed through the mammalian gut, but it did not increase or decrease germination significantly.
Sources: en.wikipedia.org
color test The quantitative analysis of a substance by comparing the intensity of the color produced when the substance is exposed to a reagent with a standard color produced similarly in a solution of known strength.
Sortase refers to a group of prokaryotic peptidases that modify surface proteins by recognizing and cleaving a carboxyl-terminal sorting signal. For most substrates of sortase enzymes, the recognition signal consists of the motif LPXTG (Leu-Pro-any-Thr-Gly), then a highly hydrophobic transmembrane sequence, followed by a cluster of basic residues such as arginine. Cleavage occurs between the Thr and Gly, with transient attachment through the Thr residue to the active site Cys residue, followed by transpeptidation that attaches the protein covalently to cell wall components. Sortases occur in almost all Gram-positive bacteria and the occasional Gram-negative bacterium (e.g. Shewanella putrefaciens) or Archaea (e.g. Methanobacterium thermoautotrophicum), where cell wall LPXTG-mediated decoration has not been reported. Although sortase A, the "housekeeping" sortase, typically acts on many protein targets, other forms of sortases recognize variant forms of the cleavage motif, or catalyze the assembly of pilins into pili.
economic development assistance should be provided primarily through loans, continuingly, and related closely to technical assistance. ... I recommend a clear separation of military and defense support assistance on the one hand, from economic development assistance on the other. ... I recommend that long[-]term development assistance be provided from a Development Loan Fund. ... Such loans should not compete with or replace such existing sources of credit [to] private investors, the International Bank [the World Bank], or the Export-Import Bank. ... I believe the Fund should be established and administered in the International Cooperation Administration. ... The technical cooperation program is one of the most valuable elements of our entire mutual security effort. It also should be continued on a long-term basis and must be closely related to the work of the Fund." As a result, the Development Loan Fund was established in August 1957. The DLF largely financed infrastructure (such as railroads, highways, and power plants), factories, and agriculture with loans whose terms were relatively "soft" in the sense of charging interest rates lower than commercial levels and being repayable in local currency rather than U.S. dollars. Some projects were financed by a combination of a DLF soft loan and a harder World Bank loan. Operationally, the DLF became administratively self-contained by 1959 after contracting for administrative support from ICA for its first two years.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.